Known targets — ChEMBL curated mechanism
CA2CA4GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Topiramate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 20/20 | 1.00 |
| ▸ | CA4 known ✓ | P22748 | 7/20 | 1.00 |
| ▸ | CA1 | P00915 | 10/20 | 1.00 |
| ▸ | CA5A | P35218 | 7/20 | 1.00 |
| ▸ | CA7 | P43166 | 7/20 | 1.00 |
| ▸ | CA9 | Q16790 | 7/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topiramate SCHEMBL7859335 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL6341452 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL18898593 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL1274751 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL17343471 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL23468160 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL5637335 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL13575742 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL4980190 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL34631 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016074-A1 | ORAL TOPIRAMATE SUSPENSION FORMULATIONS WITH EXTENDED SHELF STABILITY AND ENHANCED BIOAVAILABILITY | ROSEMONT PHARMACEUTICALS LIMITED (GB) | 2022-01-20 | — | — | US | disclosed |
| EP-3142644-A1 | ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT | Vivus, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015175982-A1 | ORALLY ADMINISTRABLE FORMULATIONS FOR THE CONTROLLED RELEASE OF A PHARMACOLOGICALLY ACTIVE AGENT | VIVUS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2579864-A1 | COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS | Synthonics, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2480669-A2 | TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY | Opko Curna, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011149757-A1 | COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS | SYNTHONICS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011038210-A2 | TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY | CURNA, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20070213352-A1 | Pyridine-containing macroheterococylic compounds as kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213352-A1 | Pyridine-containing macroheterococylic compounds as kinase inhibitors | MAP3K6, MAP3K2, MAP3K1 | CA2 2796/4885CA4 4302/4885CA1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.